TL;DR: Hydroquinone has been the gold-standard brightener for decades. Tranexamic acid is the gentler alternative quietly taking its place. Here's how they actually compare.
The 60-second answer
Hydroquinone is the brightener with the deepest evidence base — it blocks melanin production directly and works fast. Tranexamic acid (TXA) is the newer option that works on the signaling pathway instead, and it’s gentler with fewer long-term concerns. Hydroquinone hits harder, faster, but can’t be used continuously. TXA is slower but you can stay on it. Modern protocols increasingly lead with TXA and reach for hydroquinone for stubborn cases, often cycled.
How they work
Hydroquinone inhibits tyrosinase, the enzyme melanocytes use to produce melanin. It also reduces melanocyte activity directly. Used at 2% (OTC where allowed) or 4% (prescription). Decades of clinical history. In the US, it’s been prescription-only since 2020.
Tranexamic acid doesn’t block melanin production directly. It interrupts the plasminogen pathway that signals melanocytes to make more pigment in the first place — particularly the inflammatory signaling that drives melasma. It also affects the vascular component of pigmentation. Used at 2–5% topically; 250–500mg twice daily orally. Newer, with a fast-growing research base.
The key distinction: hydroquinone stops the factory. TXA quiets the orders coming in.
Side by side
| Factor | Hydroquinone | Tranexamic acid |
|---|---|---|
| Mechanism | Tyrosinase inhibition | Plasminogen pathway modulation |
| Speed | Faster (4-12 weeks) | Slower (8-16 weeks) |
| Strength | Stronger | Moderate to strong |
| Long-term safety | Risk of ochronosis with chronic use | Generally safe long-term |
| US OTC status | Restricted, Rx only | Increasingly OTC |
| Pregnancy | No | Topical generally yes; oral no |
| Long-term use | Cycled (4-6 months on, off) | Can be continuous |
| Risk profile | Higher | Lower |
When hydroquinone makes sense
Stubborn melasma that hasn’t responded to other treatments. Significant post-inflammatory hyperpigmentation that needs to move faster. Substantial sun damage. Prescription-grade formulations under a dermatologist’s eye. Cycled use — typically four to six months on, several months off. Skin tones that tolerate stronger interventions.
The non-negotiable caveat is ochronosis. Long-term continuous hydroquinone use can cause paradoxical darkening of the treated area — and once it sets in, it’s hard to reverse. This is why hydroquinone is always cycled. Four to six months on, then several months off, no exceptions. The cycling isn’t optional; it’s the safety mechanism.
When tranexamic acid makes sense
Most pigmentation concerns as the primary first-line treatment. Sensitive skin. Skin of color, where TXA is significantly less irritating than hydroquinone. Long-term maintenance, where hydroquinone would be unsafe to continue. OTC topical use when prescription access isn’t easy. Pregnancy melasma (topical only — oral is contraindicated). Combined protocols with vitamin C, niacinamide, retinoid, and SPF.
For severe melasma, the modern combined protocol — TXA plus retinoid plus vitamin C plus SPF — often matches or beats hydroquinone alone with a much better long-term safety profile.
The US regulatory situation
Hydroquinone became prescription-only in the US in 2020. Before that, 2% formulations sat on drugstore shelves. Now you need a dermatologist or telederm consultation. Some readers still self-source through imports (legally questionable). It’s available; it just isn’t sitting at CVS anymore.
Tranexamic acid is moving the opposite direction. Topical formulations are increasingly OTC and widely available — The Ordinary’s tranexamic serum, Murad’s, several K-beauty brands. Oral TXA is still prescription-only and used for melasma at 250–500mg twice daily, with the clotting-risk screening that comes with it.
What treatment timelines actually look like
Hydroquinone 4% (prescription) for melasma: visible lightening starts at 2-4 weeks, substantial improvement by 8-12 weeks, peak effect around 16 weeks. After that, you cycle off.
Topical tranexamic acid 2-5% for melasma: initial improvement at 4-8 weeks, substantial fading by 12-16 weeks, continued cumulative improvement past 6 months.
Combined TXA protocol (TXA + retinoid + vitamin C + SPF): often comparable to hydroquinone alone, more sustainable long-term, lower side-effect ceiling.
How to use either
Hydroquinone, with derm guidance: 2-4% concentrations. Once or twice daily on affected areas. Four to six months continuously. Then a two-to-three-month break, monitoring for any signs of ochronosis. Always paired with daily SPF. Often combined with tretinoin (the Triple Combination Cream — Kligman formula — adds hydrocortisone, which has its own side-effect concerns).
Topical TXA: 2-5% concentrations. Daily, AM and PM. Continuous use is safe. Pair with vitamin C, niacinamide, retinoid, SPF. The combined protocol is meaningfully stronger than TXA alone.
Oral TXA, with derm guidance: 250-500mg twice daily. Three to six month courses. Requires clotting-risk screening. Often combined with topicals for stubborn cases.
Combined protocols
The original Kligman formula combined hydroquinone 4%, tretinoin 0.05%, and hydrocortisone 1%. Effective for severe melasma. The steroid component is the concern — it’s not appropriate for indefinite use.
The modern alternative — TXA at 2-5% plus a retinoid plus vitamin C plus niacinamide plus SPF — produces comparable results with a much lower side-effect ceiling and is safer to continue indefinitely.
Skin tone considerations
For Fitzpatrick IV-VI skin, TXA is generally better tolerated than hydroquinone, ochronosis is more visible if it develops, and irritation from strong actives is more likely to leave its own pigmentation. TXA is the preferred first line for many patients with deeper skin tones. When hydroquinone is used, the cycling discipline matters more, not less.
For lighter skin, both options are viable. The combined protocol is still usually the strongest approach.
Where people get it wrong
Using hydroquinone continuously past six months. Ochronosis risk is real.
Stopping treatment the moment skin clears. Pigmentation comes back. Maintenance is part of the protocol.
Skipping SPF. Cancels every gain. Both of these molecules are functionally useless without daily sun protection.
Stacking maximum strength of both at once. Compounds irritation without compounding effect.
Buying hydroquinone from non-prescription sources. Quality and safety are unknown.
Myths worth retiring
“Hydroquinone is dangerous.” Used properly, under medical guidance, with cycling, it’s been safely used for decades. Ochronosis is preventable.
“TXA only works for melasma.” It works on multiple pigmentation types.
“Stronger is always better.” Not for skin of color, not for sensitive skin, and not for sustained results.
“Brightening can replace SPF.” It cannot.
Frequently asked questions
Should I get prescription hydroquinone? Reasonable for severe melasma that hasn’t responded to TXA. Cycle four to six months on, two to three months off.
Can I use both at the same time? With derm guidance, yes — they work through different mechanisms. Often unnecessary.
Is OTC TXA as effective as prescription strength? Topical OTC 2-5% is meaningfully effective. Prescription oral is stronger for stubborn cases.
What about kojic acid, alpha arbutin, and the others? Modest brighteners. Useful as supporting players, not primary actives.
Will my pigmentation come back if I stop treatment? Often yes, without ongoing SPF and maintenance.
Sources
Bandyopadhyay D. Topical treatment of melasma. Indian Journal of Dermatology, 2009. Bala HR et al. Oral tranexamic acid for the treatment of melasma. Dermatologic Surgery, 2018.